Borylated amino acid compositions for use in boron neutron capture therapy and methods thereof
Borylated amino acids enhance boron delivery to cancer cells, addressing BNCT limitations by improving treatment efficacy and reducing side effects through targeted neutron capture therapy.
Patent Information
- Application Number
- JP2024144188
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2019-03-04
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-03-04
AI Technical Summary
Current boron neutron capture therapy (BNCT) methods face technical limitations, including toxicity issues with existing boron compounds and challenges in delivering sufficient boron to tumor cells, leading to ineffective cancer treatment and adverse effects on normal cells.
Development of borylated amino acids (BAAs) derived from naturally occurring amino acids, such as phenylalanine, tryptophan, tyrosine, and histidine, which are synthesized to enhance boron delivery and accumulation in cancer cells, enabling targeted neutron capture therapy.
BAAs allow for higher boron concentration in tumor cells, reducing side effects on healthy tissue and improving treatment efficacy by selectively killing cancer cells while minimizing damage to normal cells.
Smart Images

Figure 2024167293000040 
Figure 2024167293000041 
Figure 2024167293000042
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 919,156, filed March 4, 2019, the contents of which are incorporated by reference in their entirety herein.
[0002] STATEMENT OF RIGHTS TO INVETIONS MADE UNDER FEDERALLY SPONSORED RESEARCH Not applicable.
[0003] FIELD OF THEINVENTION The invention described herein relates to the field of boron neutron capture therapy (BNCT). In particular, the invention relates to borylated amino acids ("BAA") or ("BAAs") compositions that can be used as vehicles for neutron capture therapy in humans. The invention further relates to the treatment of cancer and other immune disorders and diseases. [Background technology]
[0004] 2. Background of the Invention Cancer is the second leading cause of death worldwide after coronary artery disease. Millions of people die from cancer each year, with well over half a million people dying from cancer each year in the United States alone, and in 2017, 1,688,780 new cases of cancer were diagnosed (American Cancer Society). Deaths from heart disease have declined significantly, but deaths attributable to cancer in general are increasing. It is predicted that cancer will become the leading cause of death early in the next century, unless medical advances change the current trend.
[0005] Some cancers are noted for having a high mortality rate. In particular, carcinomas of the lung (18.4% of all cancer deaths), breast (6.6% of all cancer deaths), colorectal (9.2% of all cancer deaths), liver (8.2% of all cancer deaths) and stomach (8.2% of all cancer deaths) are the leading causes of cancer deaths in both sexes and at all ages worldwide (GLOBOCAN 2018). These and virtually all other carcinomas share the common fatal feature of metastasizing to sites distant from the primary tumor, and with very few exceptions, metastatic disease is fatal. Moreover, even for cancer patients who initially survive their primary cancer, the general experience indicates that their lives change dramatically. Many cancer patients experience strong anxiety due to the awareness of the possibility of recurrence or treatment failure. Many cancer patients also experience physical debilitation after treatment. Furthermore, many cancer patients experience disease recurrence.
[0006] Although cancer treatment has improved over the past decades and survival rates have increased, new therapeutic strategies utilizing multiple treatment modalities are still needed due to the heterogeneity of cancer. This is especially true for the treatment of solid tumors in anatomically important sites (e.g., glioblastoma, squamous cell carcinoma of the head and neck, and lung adenocarcinoma) that may be limited to standard radiotherapy and / or chemotherapy. Nevertheless, the deleterious effects of these therapies are chemoresistance and radioresistance, which promote locoregional recurrence, distant metastases, and another primary tumor, in addition to severe side effects that reduce the patient's quality of life.
[0007] Neutron capture therapy (NCT) is a promising form of radiation therapy. NCT is a technique that uses boron compounds to selectively kill tumor cells while sparing normal cells. BNCT uses 0.5keV <E n Non-radioactive absorbing epithermal neutrons in the low energy range <30 keV 10 Depending on the tendency of the B isotope, after neutron capture, the boron atom is converted into an α particle and a recoil lithium nucleus ( 7Li). 10 B+n→ 7 Li+ 4 He
[0008] Alpha particles deposit high energy, i.e. 150 keV / μm, along their short path essentially limited to the diameter of a single cell, resulting in double-stranded DNA breaks and subsequent cancer cell death by apoptosis. Thus, BNCT integrates both concepts of chemotherapy, targeted therapy and the macroscopic anatomical localization of traditional radiation therapy.
[0009] Although the conceptual technology of NCT, specifically boron neutron capture therapy (BNCT), is well known, progress has been slowed by the technical limitations associated with this type of treatment. During early investigations using a research reactor at MIT in the 1960s, several dosens of patients were treated using disodium decahydrodecaborate, which was thought to be less toxic than the simpler boron compounds previously used, but capable of delivering more boron to cells. Unfortunately, due to severe brain necrosis in patients undergoing BNCT and the potential hazards of using a reactor, BNCT research was halted in the United States.
[0010] In 1968, Hiroshi Hatanaka reviewed the clinical application of BNCT in Japan using sodium borocaptate (BSH) by directing light beams on surgically exposed intracranial tumors, and reported achieving a 58% 5-year survival rate. In 1987, Japanese clinicians applied BNCT for the treatment of malignant melanoma using boronophenylalanine (BPA) as the boron compound. Thus, a gradual revival of BNCT has occurred, although it is limited to countries with access to research reactor facilities capable of delivering epithermal neutron beams. Currently, NCT treatment methods are being revived due to technical improvements in both (i) injection and delivery of capture compounds that preferably collect within the tumor, and (ii) greater and easier access to neutron beams using cyclotrons.
[0011] Proton-boron fusion reaction is required for BNCT 10 B, but is abundant in nature 11 Depends on the B isotope. Unlike BNCT, it uses protons ( 1 H) and boron ( 11 B) After the fusion reaction between nuclei, three alpha particles are emitted: p+ 11 B->3α. Proton beams have the advantage of Bragg peak characteristics that reduce normal tissue damage and, when combined with proton capture, may improve the efficacy of proton therapy alone.
[0012] Boron carriers have evolved since 1950 and are reviewed in NEDUNCHEZHIAN et al., J. Clin. Diag. Res., vol. 10(12) (Dec. 2016). Briefly, the first generation of boron compounds, represented by boric acid and its derivatives, were either toxic or suffered from low tumor accumulation / retention. Both BPA and BSH are considered second generation compounds that emerged in the 1960s. They had significantly lower toxicity as well as better PK and biodistribution. BPA-fructose conjugates are considered third generation compounds that have been used since 1994 to treat patients with head and neck (H&N), glioblastoma and melanoma using BNCT. BPA-fructose and BSH are the only compounds used in clinical practice as boron carriers to date, although both low and high molecular weight biomolecules such as nucleosides, porphyrins, liposomes, nanoparticles and mAbs have been evaluated for tumor targeting in preclinical models. The main drawback of BPA-fructose, in addition to its relatively low solubility, is its rapid excretion, which prevents it from achieving a high blood Cmax, one of the factors that influences tumor uptake.
[0013] From the above description, it will be readily apparent to those skilled in the art that new treatment paradigms are needed in the treatment of cancer and immune diseases. By using modern chemical synthesis and modifying natural amino acids with boron, new disease treatments can be achieved with the overall goal of more effective treatment, reduced side effects, and reduced manufacturing costs. In view of the current deficiencies associated with NCT, it is an object of the present invention to provide new and improved methods of treating cancer, immune disorders, and other diseases utilizing borylated amino acids and NCT. [Prior art documents] [Non-patent literature]
[0014] [Non-Patent Document 1] NEDUNCHEZHIAN et al., J.Clin.Diag.Res.,vol.10(12) Summary of the Invention [Means for solving the problem]
[0015] Summary of the Invention The present invention provides compositions comprising natural amino acids borylated via chemical synthesis for use as delivery modalities for treating human diseases such as cancer, immune disorders (including but not limited to rheumatoid arthritis, ankylosing spondylitis), and other cellular diseases (including but not limited to Alzheimer's disease). In certain embodiments, the borylated amino acids are comprised of naturally occurring amino acids such as phenylalanine, tryptophan, tyrosine, histidine, and any other naturally occurring amino acid set forth in Table I.
[0016] In a further embodiment, the invention includes a method of concentrating boron in a cell, the method comprising: (i) synthesizing a borylated amino acid ("BAA"); (ii) administering the BAA to a patient; and (iii) irradiating the cell with neutrons.
[0017] In another embodiment, the present disclosure teaches a method of synthesizing a BAA.
[0018] In another embodiment, the disclosure teaches methods of treating cancer, immune disorders and other diseases in humans. In an embodiment of the present invention, for example, the following items are provided: (Item 1) The chemical structure: [ka] In the formula, E=CO2H, CONHB 12 H 11 , B(OH)2; and X=H, B(OH)2, Bpin, (-O-CH2CH2)2-OB 12 H 11 A composition comprising: (Item 2) The composition, [ka] Item 2. The composition according to item 1, comprising: (Item 3) The chemical structure: [ka] In the formula, E=CO2H, CONHB 12 H 11 , B(OH)2; and X=H, B(OH)2, Bpin, (-O-CH2CH2)2-OB 12 H 11 A composition comprising: (Item 4) The composition, [ka] 4. The composition according to item 3, comprising: (Item 5) The chemical structure: [ka] In the formula, E=CO2H, CONHB 12 H 11 , B(OH)2; and X=H, B(OH)2, Bpin, (-O-CH2CH2)2-OB 12 H 11 A composition comprising: (Item 6) The composition, [ka] 6. The composition according to item 5, comprising: (Item 7) A kit comprising the composition according to item 1. (Item 8) A kit comprising the composition according to item 2. (Item 9) A kit comprising the composition according to item 3. (Item 10) A kit comprising the composition according to item 4. (Item 11) A kit comprising the composition according to item 5. (Item 12) A kit comprising the composition according to item 6. (Item 13) Item 1. A dosage unit form comprising the composition according to item 1. (Item 14) Item 3. A dosage unit form comprising the composition according to item 2. (Item 15) A dosage unit form comprising the composition according to item 3. (Item 16) 5. A dosage unit form comprising the composition according to item 4. (Item 17) Item 6. A dosage unit form comprising the composition according to item 5. (Item 18) 7. A dosage unit form comprising the composition according to item 6. (Item 19) 14. The human unit form according to item 13, wherein the human unit form is used in boron neutron capture therapy (BNCT). (Item 20) 15. The human unit form according to item 14, wherein the human unit form is used in boron neutron capture therapy (BNCT). [Brief description of the drawings]
[0019] [Figure 1] Chemical synthesis of BPA-BS.
[0020] [Diagram 2] Chemical synthesis of BPA-BN.
[0021] [Diagram 3] Chemical synthesis of TLS00192.
[0022] [Figure 4] Chemical synthesis of TLS00178.
[0023] [Diagram 5] Chemical synthesis of TLS00190.
[0024] [Figure 6] LCMS purity and mass confirmation of TLS00192.
[0025] [Figure 7] LCMS purity and mass confirmation of TLS00178.
[0026] [Figure 8] LCMS purity and mass confirmation of TLS00190.
[0027] [Figure 9] Summary LCMS purity and mass confirmation.
[0028] [Figure 10] Kinetic parameters of TLS00192 and BPA-fructose.
[0029] [Figure 11] Cellular retention of TLS00192 and BPA-fructose in FaDu cells.
[0030] [Figure 12] LAT-1 mediated competition studies with TLS00192.
[0031] [Figure 13] Boron uptake of TLS00190 and TLS00178 in FaDu cells.
[0032] [Figure 14] Cellular retention of TLS00190, TLS00178 and BPA-fructose in FaDu cells. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0033] Detailed Description of the Invention Section Overview I.) Definition II.) BPA III.) BSH IV.) Boron a. Boron in general V.) Naturally Occurring Amino Acids VI.) Borylated Amino Acids (BAAs) a.BPA-BS b. BPA-BN C. Amino acid composition D. BAAs containing phenylalanine e. BAAs containing tryptophan f. BAAs containing tyrosine g. BAA containing histidine VII.) Boron Neutron Capture Therapy using BAA VIII.) Proton-boron fusion therapy using BAA IX.) Methods for Delivering BAAs to Cells X.) Kits / Manufactured Products
[0034] I.) Definition: Unless otherwise defined, all technical terms, notations and other scientific or terminological terms used herein are intended to have the meanings commonly understood by those skilled in the art, unless the context clearly indicates otherwise. In some cases, terms having commonly understood meanings are defined herein for clarity and / or ease of reference, and the inclusion of such definitions herein should not necessarily be construed as representing a substantial difference from what is commonly understood in the art.
[0035] When trade names are used herein, reference to a trade name also refers to the product formulation, generic drug and active pharmaceutical ingredients of that trade name product, unless the context dictates otherwise.
[0036] The terms "advanced cancer," "locally advanced cancer," "advanced disease," and "locally advanced disease" refer to cancer that has spread through the relevant tissue capsule and are meant to include stage C disease under the American Urological Association (AUA) system, stages C1-C2 disease under the Whitmore-Jewett system, and stages T3-T4 and N+ disease under the TNM (tumor, node, metastasis) system. In general, surgery is not recommended for patients with locally advanced disease, and these patients have a substantially worse prognosis compared to patients with clinically localized (organ-confined) cancer.
[0037] "Amino acid" refers to a simple organic compound that contains both a carboxyl (-COOH) and an amino (-NH2) group.
[0038] "Borylation" refers to the reaction of forming organoboron compounds through the functionalization of aliphatic and aromatic C-H bonds.
[0039] "Borylated amino acid" (BAA) refers to a compound comprising a naturally occurring amino acid, such as those shown in Table I, that has undergone a borylation reaction. BAAs can be synthesized in several ways depending on the base amino acid used.
[0040] The term "compound" refers to and includes not only the chemical compound (e.g., BAA) itself, but also, whether or not expressly stated, unless the context makes it clear that the following is to be excluded, the term refers to and includes: amorphous and crystalline forms of the compound, polymorphic forms, which may be part of a mixture or in isolated state; free acid and free base forms of the compound, typically those forms shown in the structures provided herein; isomers of the compound (refers to optical isomers and tautomers, where optical isomers include enantiomers and diastereomers, chiral isomers and non-chiral isomers, and optical isomers include isolated optical isomers, as well as mixtures of optical isomers, including racemic and non-racemic mixtures; isomers may be in isolated form or may be a mixture with one or more other isomers; isotopes of the compound, including deuterium-containing and tritium-containing compounds, including compounds that contain radioactive isotopes. , therapeutically and diagnostically effective radioisotopes; multimeric forms of the compounds, including dimeric, trimeric, etc. forms; salts of the compounds, preferably pharma- ceutically acceptable salts, including acid addition salts and base addition salts, including salts with organic and inorganic counterions, including zwitterionic forms, where in the case where the compound is associated with two or more counterions, the two or more counterions may be the same or different; and solvates, hemisolvates, monosolvates, disolvates, etc. of the compounds, including organic solvates and inorganic solvates, said inorganic solvates including hydrates; where in the case where the compound is associated with two or more solvent molecules, the two or more molecules may be the same or different. In some instances, reference herein to the compounds of the invention will include an explicit reference to one of the above forms or, for example, salts and / or solvates. However, this reference is for emphasis only and should not be construed as excluding other of the above forms identified above.
[0041] As used herein, the term "inhibit" or "inhibition of" means to decrease by a measurable amount or to completely suppress.
[0042] The term "mammal" refers to any organism classified as a mammal, including mice, rats, rabbits, dogs, cats, cows, horses, and humans. In one embodiment of the invention, the mammal is a mouse. In another embodiment of the invention, the mammal is a human.
[0043] The terms "metastatic cancer" and "metastatic disease" refer to cancer that has spread to regional lymph nodes or distant sites and are meant to include stage D disease by the AUA system and stage TxNxM+ by the TNM system.
[0044] "Molecular recognition" refers to a chemical event by which a host molecule can form a complex with a second molecule (i.e., a guest). This process occurs through non-covalent chemical bonds, including but not limited to hydrogen bonding, hydrophobic interactions, and ionic interactions.
[0045] "Pharmaceutically acceptable" refers to a non-toxic, inert, and / or composition that is physiologically compatible with humans or other mammals.
[0046] The term "neutron capture agent" means a stable, non-reactive chemical isotope that produces alpha particles when activated by a neutron.
[0047] The term "neutron capture therapy" refers to a non-invasive therapeutic modality for treating locally invasive malignancies, such as primary brain tumors and recurrent head and neck cancer, as well as other immune disorders and diseases, by irradiating a neutron capture agent with neutrons.
[0048] As used herein, "treat" or "therapeutic" and grammatically related terms refer to any improvement in any outcome of a disease, such as extending survival, reducing morbidity, and / or reducing side effects that are a by-product of alternative treatment modalities; as will be readily understood in the art, complete eradication of the disease, although preferred, is not a requirement of the act of treatment.
[0049] II.) BPA
[0050] For reference, ( 10 B) -BPA, L-BPA or 4-borono-L-phenylalanine (Sigma Aldrich, St. Louis, MO) has the chemical formula CH 12 It is a synthetic compound with the structure: [ka] and is an important boronated compound useful in the treatment of cancer by BNCT. It is a widely known compound for which many syntheses have been developed (U.S. Pat. No. 8,765,997, Taiwan Biotech Co, Ltd., Taoyuan Hsein, Taiwan, and U.S. Patent Application Publication No. 2017 / 0015684, Stella Pharma Corp., Osaka Prefecture, Japan). (See University of Tokyo, Osaka, Japan).
[0051] III.) BSH In addition, BSH, or sodium borocaptate, or BSH sodium borocaptate, or sodium borocaptate 10 B, or undecahydrododecaboranethiol, has the chemical formula NaB 12 H 11 It is a synthetic chemical compound that contains SH. Its structure is as follows: [ka] The BSH is shown in Figure 1, where the boron atoms are represented by dots at the vertices of the icosahedron. BSH is used as a capture agent in BNCT. Generally speaking, BSH is injected intravenously and concentrated in the tumor cells. The patient then undergoes radiation treatment with atomic particles called neutrons. The neutrons fuse with the boron nuclei in the BSH, producing high-energy alpha particles that kill the tumor cells.
[0052] IV.) Boron (a.) Boron in general Generally speaking, for the purposes of this disclosure, boron is a chemical element with the symbol B and atomic number 5. Natural boron, used primarily in chemical compounds, is composed of two stable isotopes, one of which is boron-10 and the other is boron-11. The boron-10 isotope is useful for capturing epithermal neutrons, making it a promising tool in therapeutic settings using boron neutron capture therapy. Biologically, the borylated compounds disclosed herein are non-toxic to humans and animals. Based on the above, it will be apparent to those skilled in the art that an improved manner for providing high concentrations of boron in cancer cells would be advantageous. It is an object of the present disclosure to provide such advantages.
[0053] V.) Naturally Occurring Amino Acids Generally speaking, for the purposes of this disclosure, naturally occurring amino acids are organic compounds that contain amine (-NH2) and carboxyl (-COOH) functional groups along with a side chain (R group) specific to each amino acid. The essential elements of amino acids are carbon (C), hydrogen (H), oxygen (O) and nitrogen (N), although other elements are found in the side chains of certain amino acids. There are approximately 500 naturally occurring amino acids known (although only 20 appear in the genetic code (Table I)), which can be classified in many ways. They can be classified according to the location of the core structural functional group as alpha- (α-), beta- (β-), gamma- (γ-) or delta- (δ-) amino acids, with other categories relating to polarity, pH level and type of side chain group (aliphatic, acyclic, aromatic, hydroxyl-containing or sulfur-containing, etc.). In the form of proteins, amino acid residues form the second most abundant component (water is the most abundant) of human muscle and other tissues. Beyond their role as residues in proteins, amino acids are involved in many processes such as neurotransmitter transport and biosynthesis.
[0054] The twenty (20) amino acids directly encoded by the genetic code (see Table I) can be divided into several groups based on their properties. Important factors are charge, hydrophilicity or hydrophobicity, size and functional group. These properties are important for protein structure and protein-protein interactions. Water-soluble proteins tend to have their hydrophobic residues (Leu, Ile, Val, Phe and Trp) buried in the center of the protein, while the hydrophilic side chains are exposed to the aqueous solvent.
[0055] Integral membrane proteins tend to have an exposed outer ring of hydrophobic amino acids that anchor them to the lipid bilayer. In between these two extremes, some peripheral membrane proteins have patches of hydrophobic amino acids on their surface that anchor them on the membrane. Similarly, proteins that must bind positively charged molecules have a surface rich in negatively charged amino acids such as glutamic acid and aspartic acid, while proteins that bind negatively charged molecules have a surface rich in positively charged chains such as lysine and arginine. There are different hydrophobic scales of amino acid residues.
[0056] Some amino acids have special properties, such as cysteine, which can form covalent disulfide bonds to other cysteine residues, proline, which forms rings into the polypeptide backbone, and glycine, which is more flexible than other amino acids.
[0057] VI.) Borylated Amino Acids (BAAs) As a brief introduction and to better understand the background of the inventive efforts of this disclosure, large neutral amino acid transporter 1 (LAT-1, SLC7a5) is a sodium-independent and pH-independent transporter that supplies essential amino acids (e.g., leucine, phenylalanine) to cells. The functional transporter is a heterodimeric disulfide-linked complex composed of the multi-membrane-spanning subunit SLC7a5 and the single-membrane-spanning subunit SLC3a2 (CD98). LAT-1 is the primary transporter for channeling essential amino acids across such compartments, such as the placenta or blood-brain barrier. In addition, LAT-1 also transports the thyroid hormones T3 and T4 (see FRIESEMA et al., Endocrinology, 142(10):4339-4348 (2001)), the dopamine precursor L-DOPA, and amino acid-related exogenous compounds such as the drugs melphalan and gabapentin (see UCHINO et al., Mol. Pharmacol 61:729-737 (2002)). Moreover, its expression is highly upregulated in various types of human cancers characterized by a strong requirement for amino acids for metabolism and growth (see SINGH et al., Int. J. Mol. Sci. 2018, 19, 1278). Furthermore, it has been reported that the nature of the amino acid side chain affects the selectivity of LAT-1 for various amino acids in the following order with respect to increasing the transport rate: Phe>Trp>Leu>Ile>Met>His>Tyr>Val (see KANAI et al., J. Biol. Chem., vol. 273, No. 37, pp. 23629-23632 (1998)). However, the effect of boron-added modifications on amino acids was not known in the art, and the present disclosure represents a breakthrough.
[0058] The therapeutic potential of BNCT as an effective cancer treatment depends on the presence of sufficient amounts of 10 It is based on the selective accumulation of B.
[0059] Based on the above, those skilled in the art have shown that essential amino acid transporter proteins such as LAT1 are responsible for the uptake of certain natural amino acids. See SCALISE et al., Frontiers in Chem.Vol.6,Art.243 (June 2018). With this principle in mind, the present disclosure contemplates the synthesis of natural amino acids through borylation reactions to create borylated amino acids ("BAAs") with tumor-seeking and tumor-localizing properties for use as neutron capture agents in boron-proton capture therapy, commonly known as boron neutron capture therapy ("BNCT") and / or proton-boron fusion therapy ("PBFT"). See, for example, HATTORI et al., J.Med.Chem.,55,6980-6984 (2012).
[0060] (a) BPA-thioundecahydro-dodecaborane, i.e., BPA-BS In one embodiment, within the scope of the present disclosure is a precursor composition having the following formula: [ka]
[0061] Those skilled in the art will appreciate that the above compositions are precursors to more complex branched BAAs that use additional natural amino acids such as phenylalanine, tryptophan, tyrosine and / or histidine. Synthesis of BPA-BS, shown in Figure 1, can be accomplished by peptide coupling conditions using Fmoc-pretected BPA, followed by deprotection to reveal the target material.
[0062] (b) BPA-aminoundecahydrododecaborane, or BPA-BN. In one embodiment, within the scope of the present disclosure is a second precursor composition having the following formula: [ka]
[0063] Those skilled in the art will appreciate that the BPA-BN precursor is a modification of BPA-BS and is a further precursor to more complex branched BAAs using additional natural amino acids such as phenylalanine, tryptophan, tyrosine and / or histidine. The synthesis is carried out as shown in Figure 2. For further reference, see KIRIHATA et al., 18 th See International BNCT Conference, Taipei (October 2018). The synthesis of these compounds can be achieved by peptide coupling between Fmoc-protected BPA and undecahydrododecaboric ammonia, followed by deprotection to reveal the target material.
[0064] The precursors of the present disclosure can be utilized to synthesize BAAs with functional incorporation in specific complexes to deliver concentrated amounts of boron to cancer or other diseased cells for use in BNCT and / or other cancer treatment modalities. In the present disclosure, in one embodiment, the amino acids include valine, leucine, isoleucine, histidine, tryptophan, tyrosine, and any set of amino acids listed in Table I.
[0065] This principle can be achieved through side chain manipulation, peptide coupling and decarboxylation-borolation. See LI et al., Science 356, 1045 (2017); Synlett 1996(02):167-168; and US Patent Application Publication No. 2018 / 0155368 (Neuboron Medtech, Nanjing, China). The wide variety of useful reactivities specific to boronic acids, such as cross-coupling, oxidation, amination and homologation, have been shown to guide retrosynthetic analysis. Manipulation of solubility and lipophilicity through the use of boronic esters instead of acids is also contemplated in the present disclosure. Following the modifications disclosed herein, additional antigen complexes and transporters can be implicated through selective boronation of their respective molecular substrates.
[0066] (c) Amino acid composition In one embodiment, within the scope of the present disclosure are BAAs having the following formula ("phenylalanine derivatives"): [ka] In the formula, E=CO2H, CONHB 12 H 11 , B(OH)2; and X=H, B(OH)2, Bpin, (-O-CH2CH2)2-OB 12 H 11 .
[0067] In further embodiments, within the scope of the present disclosure are BAAs having the following formula ("histidine derivatives"): [ka] In the formula, E=CO2H, CONHB 12 H 11 , B(OH)2; and X=H, B(OH)2, Bpin, (-O-CH2CH2)2-OB 12 H 11 .
[0068] In further embodiments, within the scope of the present disclosure are BAAs having the following formula ("tyrosine derivatives"): [ka] In the formula, E=CO2H, CONHB 12 H 11 , B(OH)2; and X=H, B(OH)2, Bpin, (-O-CH2CH2)2-OB 12 H 11 .
[0069] In a further embodiment, within the scope of the present disclosure are BAAs having the following formula: [ka]
[0070] (d) BAA containing phenylalanine Phenylalanine has the following chemical formula: [ka] It is an essential amino acid with a phenylalanine-binding domain and is a precursor of the amino acid tyrosine. Phenylalanine is highly concentrated in the human brain and plasma. High plasma concentrations of phenylalanine affect blood-brain barrier transport of large neutral amino acids. High plasma phenylalanine concentrations increase the influx of phenylalanine into the brain and constrain the influx of other large neutral amino acids. Phenylalanine has been found to interfere with various brain enzyme systems. Phenylalanine is known to be better absorbed and less likely to cause headaches than tyrosine. Certain cancers are known to use more phenylalanine than other types of cancer. For example, melanoma has been shown to utilize higher concentrations of phenylalanine.
[0071] Thus, the use of borylated phenylalanines as neutron capture agents in certain cancers is contemplated by the present disclosure.
[0072] In one embodiment of the present disclosure, the ferrylalanine-containing BAA has the following chemical formula: [ka] Note that the dots in structure IV represent BH. The black dot at one vertex represents B. The B12H11 cluster has a net charge of -2.
[0073] (e) Tryptophan-containing BAAs Tryptophan has the following chemical formula: [ka] It is an essential amino acid with tryptophan and is the precursor of both serotonin and melatonin. Melatonin is a hormone produced by the mammalian pineal gland that regulates sleep and wakefulness. Serotonin is a neurotransmitter in the brain, a platelet clotting factor, and a neurohormone found in organs throughout the body. There are many conditions or diseases that are characterized by tryptophan deficiency.
[0074] For example, fructose malabsorption causes improper absorption of tryptophan in the intestine, lowering the levels of tryptophan in the blood, resulting in depression. A high corn or other tryptophan deficient diet can cause pellagra, a niacin-tryptophan deficiency disease with symptoms of dermatitis, diarrhea, and dementia. Hartnup disease is a disorder in which tryptophan and other amino acids are not properly absorbed. Symptoms of Hartnup disease include skin rashes, difficulty with coordination (cerebellar ataxia), and psychiatric symptoms (such as depression or psychosis). Tryptophan plays a role in "meal-induced" sleepiness. Ingestion of a carbohydrate-rich meal causes the release of insulin. Insulin then stimulates the uptake of large neutral branched-chain amino acids (BCAAs) into muscles, increasing the ratio of tryptophan to BCAAs in the bloodstream. Increasing the tryptophan ratio reduces competition at the large neutral amino acid transporter (which transports both BCAAs and tryptophan), resulting in greater uptake of tryptophan across the blood-brain barrier into the cerebrospinal fluid (CSF). Once in the CSF, tryptophan is converted to serotonin, which is further metabolized by the pineal gland to melatonin, which promotes sleep.
[0075] Thus, the use of borylated tryptophan as a neutron capture agent in certain cancers is contemplated by the present disclosure.
[0076] In one embodiment of the present disclosure, the tryptophan-containing BAA has the following chemical formula: [ka]
[0077] (f) Tyrosine-containing BAAs Tyrosine has the following chemical formula: [ka] It is an essential amino acid with a tyrosine-binding domain and is known to easily cross the blood-brain barrier. Once in the brain, tyrosine is the precursor of the neurotransmitters dopamine, norepinephrine and epinephrine (better known as adrenaline). These neurotransmitters are an important part of the body's sympathetic nervous system, and their concentrations in the body and brain are directly dependent on dietary tyrosine. Tyrosine is rapidly metabolized. Folic acid, copper and vitamin C are cofactor nutrients for these reactions. Tyrosine is also a precursor of the hormones, thyroid and catechol estrogens and the major human pigment, melanin. Tyrosine is an important amino acid in many proteins, peptides and even in the body's natural painkillers, enkephalins. Valine and other branched amino acids, and possibly tryptophan and phenylalanine, can reduce tyrosine absorption. Many genetic errors of tyrosine metabolism occur, such as hawkingsinuria and tyrosinemia type I. The most common is increased tyrosine in the blood of premature infants, which are characterized by reduced motor activity, lethargy and poor feeding. Infections and intellectual disability may occur. Some adults also develop elevated blood tyrosine levels, indicating a need for more vitamin C. Generally speaking, tyrosine is needed under stress, and tyrosine supplements may suppress stress-induced depletion of norepinephrine and cure biochemical depression.
[0078] Thus, the use of borylated tyrosine as a neutron capture agent in certain cancers is contemplated by the present disclosure.
[0079] In one embodiment of the disclosure, the tyrosine-containing BAA has the following chemical formula: [ka]
[0080] (g) Histidine-containing BAA Histidine has the following chemical formula: [ka] Histidine is an α-amino acid with an imidazole functional group. Histidine is one of the twenty-two (22) amino acids that make up proteins. Histidine is an essential amino acid in humans and other mammals. Histidine is a precursor for the biosynthesis of histamine and carnosine. There are inborn errors of histidine metabolism, including histidinemia, maple syrup urine disease, propionic acidemia, and tyrosinemia type I, which are characterized by increased levels of histidine in the blood. Elevated blood histidine is accompanied by a wide range of symptoms, from mental and physical retardation to reduced intellectual function, emotional lability, tremor, ataxia, and psychosis. Histidine and other imidazole compounds have antioxidant, anti-inflammatory, and anti-secretory properties. The effectiveness of L-histidine in protecting inflamed tissues is due to the ability of the imidazole ring to scavenge reactive oxygen species (ROS) generated by cells during acute inflammatory responses. Histidine, when administered in therapeutic amounts, can inhibit cytokines and growth factors involved in cell and tissue damage (see U.S. Patent No. 6,150,392, THOMES et al.). Histidine in medical treatment has had its most promising trials in rheumatoid arthritis, where up to 4.5 g per day has been used effectively in severely affected patients. Arthritis patients have been found to have low serum histidine levels, apparently due to the very rapid removal of histidine from the blood. Other patients besides arthritis patients who have been found to have low serum histidine are those with chronic renal failure. Urinary levels of histidine are reduced in pediatric patients with pneumonia. Asthma patients show increased serum levels of histidine than normal controls. Serum histidine levels are lower and negatively associated with inflammation and oxidative stress in obese women. Histidine supplementation has been shown to reduce insulin resistance, reduce BMI and fat mass, and inhibit inflammation and oxidative stress in obese women with metabolic syndrome. Histidine appears to suppress proinflammatory cytokine expression in adipocytes, possibly via the NF-κB pathway.Low plasma concentrations of histidine are associated with protein-energy wasting, inflammation, oxidative stress, and greater mortality in patients with chronic kidney disease.Histidine may have many other possible functions, since it is the precursor of histamine, a ubiquitous neurohormone-neurotransmitter. Histidine increases histamine in the blood and potentially in the brain. Low blood histamine with low serum histidine occurs in rheumatoid arthritis patients. Low blood histamine also occurs in some manic, schizophrenic, high copper and hyperactive groups of psychiatric patients.
[0081] Thus, the use of borylated histidine as a neutron capture agent in certain cancers is contemplated by the present disclosure.
[0082] In one embodiment of the present disclosure, the histidine-containing BAA has the following chemical formula: [ka]
[0083] VII.) Boron Neutron Capture Therapy using BAA One aspect of the present disclosure is the use of BAA as a modality for boron neutron capture therapy (BNCT) and / or boron proton capture therapy ("BPCT"). Briefly, BNCT is a two-component treatment modality where neither component alone is lethal or toxic to the tumor. The two components include (i) injection or delivery of a capture compound that preferentially concentrates in the tumor, and (ii) irradiation of the tumor site with neutrons or with protons. In BNCT: 10 In view of the large cross section of thermal neutron interaction with B, the result is that the boron nucleus 4 He 2+ and 7 Li + He 2+ and Li +Given the high ionization capacity of boron and the short distance traveled, cells favorably enriched with boron are killed, while healthy cells are much less damaged due to the lack of high concentrations of boron. In view of this, the advantage of BNCT is that it destroys tumor cells without highly traumatic surgical procedures. However, as will be appreciated by those skilled in the art, success depends on the degree of damage to the tumor cells. 10 This is based on the selective localization of B at high concentrations.
[0084] In one embodiment, 10 B is concentrated on the BAA. The BAA is then administered to a patient and the BAA localizes in tumor cells. 10 B-containing BAAs are concentrated in the tumor and epithermal neutrons are used to irradiate the tumor. Tumor cells are destroyed.
[0085] VIII. Proton-boron fusion therapy using BAA Another aspect of the present disclosure is the use of BAA as a modality for proton-boron fusion therapy (PBFT). Briefly, the proton-boron fusion reaction was introduced in the 1960s. 1 H) and boron particles ( 11After the reaction between A and B), three α particles are released. These three α particles damage the tumor cells, similar to the case of α particles in BNCT. Theoretically, for PBFT, the therapeutic efficacy per incident particle is three times (3×) greater than that of BNCT. In addition, proton beams have the advantage of Bragg peak characteristics, so normal tissue damage can be reduced. Generally speaking, many studies have been conducted for tumor treatment with α particles. In order to utilize α particles for dose delivery, two important points should be considered. First, boron uptake should be accurately labeled to the target cells. As mentioned above, α particles are generated at the site where the boronate compound accumulates. If this occurs in normal tissues near the tumor area, the α particles will damage not only the tumor cells but also the normal tissues. Secondly, the number of α particles generated is also an important factor for effective treatment. By using PBFT, a more effective treatment can be achieved compared to BNCT or conventional proton therapy alone.
[0086] In one embodiment, 10 B and / or 11 B is concentrated on the BAA. The BAA is then administered to a patient and the BAA localizes in tumor cells. 10 B and / or 11 B-containing BAAs are concentrated in the tumor and epithermal neutrons are used to irradiate the tumor. Tumor cells are destroyed.
[0087] IX. Methods of Delivering BAAs to Cells As will be appreciated by those skilled in the art, it is an advantage of the present invention that high concentrations of boron can be efficiently delivered to cells.
[0088] The BAA of the present disclosure has been shown to allow safe administration of higher amounts of boron to cells in mammals.Briefly, the BAA of the present disclosure is prepared as described in the present disclosure.The obtained BAA is taken up by tumor cells through upregulated LAT-1 transporter protein.
[0089] X.) Kits / Manufactured Products For use in the laboratory, prognostic, preventive, diagnostic and therapeutic applications described herein, kits are within the scope of the present invention. Such kits can include a carrier, package or container that is compartmentalized to receive one or more containers, such as vials, tubes, each of which includes one of the separate elements to be used in the method, along with a label or insert that includes instructions for use, such as the uses described herein. For example, the container can include one BAA or several BAAs of the present disclosure. The kit can include a container that includes a drug unit. The kit can include all or part of the BAA and / or a diagnostic assay for detecting cancer and / or other immune disorders.
[0090] Kits of the present invention typically include the above-mentioned container and one or more other containers associated with the above-mentioned container with equipment desirable from a commercial and user standpoint, such as buffers, diluents, filters, needles, syringes, etc., labels on the carriers, packages, containers, vials and / or tubes listing the contents and / or instructions for use, and package inserts containing the instructions for use.
[0091] A label can be present on or with the container to indicate that the composition is used for a particular therapeutic or non-therapeutic application, such as prognostic, preventive, diagnostic or laboratory application, and can also indicate instructions for either in vivo or in vitro use, such as those described herein. Instructions and / or other information can also be included on an insert or label included with or on the kit. The label can be present on the container or associated with the container. The label can be present on the container if the letters, numbers or other characters forming the label are molded or etched into the container itself, or the label can be associated with the container if the label is present in a receptacle or carrier that also holds the container, such as as a package insert. The label can indicate that the composition is used to diagnose, treat, prevent or prognose a condition, such as cancer or other immune disorder.
[0092] The terms "kit" and "article of manufacture" may be used synonymously.
[0093] In another embodiment of the present invention, one or more articles of manufacture contain the composition such as the BAA of the present disclosure. The article of manufacture typically includes at least one container and at least one label. Suitable containers include, for example, bottles, vials, syringes and test tubes. The container can be made of various materials such as glass, metal or plastic. The container can hold one or more BAAs and / or one or more therapeutic doses of the BAA.
[0094] Alternatively, the container may hold a composition effective for treating, diagnosing, prognosing or preventing a condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The active agent in the composition may be a BAA of the disclosure.
[0095] The article of manufacture may further include a second container comprising a pharma- ceutically acceptable buffer, such as phosphate buffered saline, Ringer's solution, and / or dextrose solution. The article of manufacture may further include other buffers, diluents, filters, stirrers, needles, syringes, and / or other equipment desirable from a commercial and user standpoint, including package inserts with directions and / or instructions for use.
[0096] Further embodiments of the disclosure herein include those described in the following sections. Item 1 is an embodiment of a composition comprising the following chemical structure: [ka] In the formula, E=CO2H, CONHB 12 H 11 , B(OH)2; and X=H, B(OH)2, Bpin, (-O-CH2CH2)2-OB12 H 11 .
[0097] Item 2 is the composition, [ka] An embodiment of the composition includes:
[0098] Item 3 is an embodiment of a composition comprising the following chemical structure: [ka] In the formula, E=CO2H, CONHB 12 H 11 , B(OH)2; and X=H, B(OH)2, Bpin, (-O-CH2CH2)2-OB 12 H 11 .
[0099] Item 4 is the composition, [ka] An embodiment of the composition includes:
[0100] Item 4 is an embodiment of a composition comprising the following chemical structure: [ka] In the formula, E=CO2H, CONHB 12 H 11 , B(OH)2; and X=H, B(OH)2, Bpin, (-O-CH2CH2)2-OB 12 H 11 .
[0101] Item 5 is a method for producing the composition, [ka] An embodiment of the composition includes:
[0102] Item 6 is an embodiment of a kit comprising the composition of item 1.
[0103] Item 7 is an embodiment of a kit comprising the composition of item 2.
[0104] Item 8 is an embodiment of a kit comprising the composition of item 3.
[0105] Item 9 is an embodiment of a kit comprising the composition of item 4.
[0106] Item 10 is an embodiment of a kit comprising the composition of item 5.
[0107] Item 11 is an embodiment of a kit comprising the composition of item 6.
[0108] Item 12 is an embodiment of a dosage unit form comprising the composition of item 1.
[0109] Item 13 is an embodiment of a dosage unit form comprising the composition of item 2.
[0110] Item 14 is an embodiment of a dosage unit form comprising the composition of item 3.
[0111] Item 15 is an embodiment of a dosage unit form comprising the composition of item 4.
[0112] Item 16 is an embodiment of a dosage unit form comprising the composition of item 5.
[0113] Item 17 is an embodiment of a dosage unit form comprising the composition of item 6.
[0114] Item 18 is an embodiment of the human unit form of item 12, wherein the human unit form is used in boron neutron capture therapy (BNCT).
[0115] Item 19 is an embodiment of the human unit form of item 13, wherein the human unit form is used in boron neutron capture therapy (BNCT).
[0116] Item 20 is an embodiment of the human unit form of item 14, wherein the human unit form is used in boron neutron capture therapy (BNCT).
[0117] Item 21 is an embodiment of the human unit form of item 15, wherein the human unit form is used in boron neutron capture therapy (BNCT).
[0118] Item 22 is an embodiment of the human unit form of item 16, wherein the human unit form is used in boron neutron capture therapy (BNCT).
[0119] Item 23 is an embodiment of the human unit form of item 17, wherein the human unit form is used in boron neutron capture therapy (BNCT).
[0120] Item 24 is an embodiment of a method for producing the composition of item 1.
[0121] Item 25 is an embodiment of a method for producing the composition of item 2.
[0122] Item 26 is an embodiment of a method for producing the composition of item 3.
[0123] Item 27 is an embodiment of a method for producing the composition of item 4.
[0124] Item 28 is an embodiment of a method for producing the composition of item 5.
[0125] Item 29 is an embodiment of a method for producing the composition of item 6.
[0126] Term 30 is the following formula: [ka] In one embodiment, the borylated amino acid ("BAA") has the formula:
[0127] Item 31 is an embodiment of a method for producing the composition of item 30.
[0128] Item 32 is an embodiment of a method for performing boron neutron capture therapy ("BNCT") on a mammal, comprising concentrating a BAA in a cell, the method comprising: (i) administering the BAA to a subject; and (iii) irradiating the cell with neutrons.
[0129] Item 33 is an embodiment of a method of performing boron neutron capture therapy ("BNCT") on a mammal, comprising concentrating a BAA in a cell, the method comprising: (i) administering a BAA to a subject; and (iii) irradiating the cell with neutrons, the BAA comprising the composition of item 1.
[0130] Item 34 is an embodiment of a method of performing boron neutron capture therapy ("BNCT") on a mammal, comprising concentrating a BAA in a cell, the method comprising: (i) administering a BAA to a subject; and (iii) irradiating the cell with neutrons, the BAA comprising the composition of item 2.
[0131] Item 35 is an embodiment of a method of performing boron neutron capture therapy ("BNCT") on a mammal, comprising concentrating a BAA in a cell, the method comprising: (i) administering a BAA to a subject; and (iii) irradiating the cell with neutrons, the BAA comprising the composition of item 3.
[0132] Item 36 is an embodiment of a method of performing boron neutron capture therapy ("BNCT") on a mammal, comprising concentrating a BAA in a cell, the method comprising: (i) administering a BAA to a subject; and (iii) irradiating the cell with neutrons, the BAA comprising the composition of item 4.
[0133] Item 37 is an embodiment of a method of performing boron neutron capture therapy ("BNCT") on a mammal, comprising concentrating a BAA in a cell, the method comprising: (i) administering a BAA to a subject; and (iii) irradiating the cell with neutrons, the BAA comprising the composition of item 5.
[0134] Item 38 is an embodiment of a method of performing boron neutron capture therapy ("BNCT") on a mammal, comprising concentrating a BAA in a cell, the method comprising: (i) administering a BAA to a subject; and (iii) irradiating the cell with neutrons, the BAA comprising the composition of item 6.
[0135] Paragraph 39 is an embodiment of a method of performing boron neutron capture therapy ("BNCT") on a mammal, comprising concentrating a BAA in a cell, the method comprising: (i) administering a BAA to a subject; and (iii) irradiating the cell with neutrons, the BAA comprising the composition of paragraph 30.
[0136] Item 40 is an embodiment of a method of performing neutron capture therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borolyated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with neutrons.
[0137] Item 41 is an embodiment of a method of performing neutron capture therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with neutrons, wherein the BAA is the composition of item 1.
[0138] Item 42 is an embodiment of a method of performing neutron capture therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with neutrons, wherein the BAA is the composition of item 2.
[0139] Item 43 is an embodiment of a method of performing neutron capture therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with neutrons, wherein the BAA is the composition of item 3.
[0140] Item 44 is an embodiment of a method of performing neutron capture therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with neutrons, wherein the BAA is the composition of item 4.
[0141] Item 45 is an embodiment of a method of performing neutron capture therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with neutrons, wherein the BAA is the composition of item 5.
[0142] Paragraph 46 is an embodiment of a method of performing neutron capture therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with neutrons, wherein the BAA is the composition of paragraph 6.
[0143] Paragraph 47 is an embodiment of a method of performing neutron capture therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with neutrons, wherein the BAA is the composition of paragraph 30.
[0144] Item 48 is an embodiment of the method for performing neutron capture therapy according to any one of items 40 to 47, wherein the neutron capture therapy is boron neutron capture therapy.
[0145] Item 49 is an embodiment of the method for performing neutron capture therapy according to any one of items 40 to 47, wherein the irradiation includes epithermal neutrons.
[0146] Item 50 is an embodiment of a method of performing proton boron fusion therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borolyated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with protons.
[0147] Item 51 is an embodiment of a method of performing proton boron fusion therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with protons, wherein the BAA comprises the composition of item 1.
[0148] Item 52 is an embodiment of a method of performing proton boron fusion therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with protons, wherein the BAA comprises the composition of item 2.
[0149] Item 53 is an embodiment of a method of performing proton boron fusion therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with protons, wherein the BAA comprises the composition of item 3.
[0150] Item 54 is an embodiment of a method of performing proton boron fusion therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with protons, wherein the BAA comprises the composition of item 4.
[0151] Item 55 is an embodiment of a method of performing proton boron fusion therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with protons, wherein the BAA comprises the composition of item 5.
[0152] Item 56 is an embodiment of a method of performing proton boron fusion therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with protons, wherein the BAA comprises the composition of item 6.
[0153] Paragraph 57 is an embodiment of a method of performing proton boron fusion therapy in the treatment of human cancer, comprising: (a) synthesizing a human unit dose of a borylated amino acid (BAA) composition; (b) injecting the BAA into a tumor, whereby the BAA accumulates intracellularly; and (c) irradiating the BAA with protons, wherein the BAA comprises the composition of paragraph 30. EXAMPLES
[0154] Working Example: Various aspects of the present invention are further described and illustrated by the following several examples, none of which are intended to limit the scope of the invention.
[0155] Example 1: Synthesis of BAA No. 1 containing phenylalanine. The phenylalanine-containing BAA #1 is synthesized as follows: the protected BPA is subjected to decarboxylation-borylation and then deprotected to reveal the target product.
[0156] BAA number 1, which contains phenylalanine, has the following chemical structure: [ka]
[0157] Example 2: Synthesis of histidine-containing BAA number 2. The histidine-containing BAA number 2 is synthesized in the following manner: the protected histidine is subjected to decarboxylation-borylation and then deprotected to reveal the target substance.
[0158] BAA number 2, which contains histidine, has the following chemical structure: [ka]
[0159] Example 3: Synthesis of histidine-containing BAA number 3. The histidine-containing BAA number 3 is synthesized in the following manner: the protected histidine succinate is subjected to nucleophilic addition with BNH, followed by deprotection to reveal the target.
[0160] BAA number 3, which contains histidine, has the following chemical structure: [ka]
[0161] Example 4: Synthesis of histidine-containing BAA number 4. The histidine-containing BAA number 4 is synthesized in the following manner: the protected histidine is subjected to organolithiation, then added to trimethylborate, and then deprotected to reveal the target material.
[0162] BAA number 4, which contains histidine, has the following chemical structure: [ka]
[0163] Example 5: Synthesis of TLS00192. The following protocol was used to synthesize the BAA compound known as TLS00192 (see Figure 3). First, triethylamine is added to a solution of tyrosine methyl ester in dichloromethane, followed by di-tert-butyl dicarbonate. After completion of the reaction, unreacted starting materials are removed in an acidic wash, and then the solvent is removed under reduced pressure.
[0164] The isolated boc-tyrosine methyl ester was then added to a solution of DMF and potassium carbonate, followed by the addition of methyl iodide. Once the reaction was complete, it was diluted with water, extracted into ethyl acetate, and the organic layer was washed with saturated aqueous NaCl and dried over anhydrous sodium sulfate.
[0165] The protected tyrosine compound was then added to a mixture of iodine and silver sulfate in methanol. When the reaction was complete, the precipitate was removed by filtration. The filtrate was washed with 10% aqueous sodium bisulfite solution, then with water. After drying over anhydrous sodium sulfate, the solvent was removed under reduced pressure. The product was isolated by column chromatography on silica gel.
[0166] The catalyst Pd(dppf)Cl2, bis(pinacolato)diboron and potassium acetate in DMSO were then added, and the system was then flushed with nitrogen. A DMSO solution of iodo-tyrosine was then added to the reaction, and the temperature was brought to 80° C. The product was extracted into ethyl acetate with water washes, dried over magnesium sulfate, filtered, and the solvent was removed under reduced pressure.
[0167] The pinacol boronated tyrosine was then solubilized in acetone, to which NaIO4 was added. After stirring the reaction mixture for 15 min, 1M HCl was added and the reaction was stirred for 4 h. The resulting mixture was extracted with EtOAc, washed with deionized water, and finally with brine. The organic layer was dried over MgSO4. After filtration, the organic solvent was removed under vacuum.
[0168] A solution of the boronate methyl ether tyrosine synthesized above in DCM was then brought to -78°C and flushed with nitrogen. Boron tribromide was added dropwise to the mixture and allowed to react for 12 hours. The reaction was poured into water, extracted, dried over magnesium sulfate, and then the solvent was removed under vacuum.
[0169] Finally, the tyrosine methyl boronic acid ester was placed in a 3:1 solution of THF:water. LiOH was added and the reaction was allowed to proceed until only the target material was observed. The solution was neutralized with HCl and the solvent was removed under reduced pressure.
[0170] TLS00192 has the following chemical structure: [ka]
[0171] Example 6: Synthesis of TLS00178. The following protocol was used to synthesize the BAA compound known as TLS00178 (see Figure 4). First, 1-ammine-undecahydrododecaborate is added to a DMF solution at 0°C, followed by portionwise addition of sodium hydride. Once gas evolution has ceased, a boc-protected succinimide ester of histidine is added. After concentration, the material is telescoped forward. 4 molar HCl in dioxane is added to the material, followed by 12% water by volume. Once the reaction is fully converted, as monitored by LCMS, the solvent is removed under reduced pressure. The target material is obtained by trituration with ethanol.
[0172] TLS00178 has the following chemical structure: [ka]
[0173] Example 7: Synthesis of TLS00190. The following protocol was used to synthesize the BAA compound known as TLS00190 (see Figure 5). First, the boc-protected methyl ester of tyrosine is added to a solution of acetonitrile / water, 20% v / v at 50°C. Potassium carbonate is then added to the solution and allowed to react for 15 minutes. 1-(1,4-dioxane)-undecahydrododecaborate. The reaction is allowed to proceed overnight. The solvent is exchanged to MeOH / water, 20% v / v. Lithium hydroxide is added and the solution is refluxed. Once no more methyl ester is observed, the reaction is neutralized with HCl and the solvent is removed. This material is dissolved in 4 molar HCl in dioxane and 20% v / v water is added to it. The target material is obtained by preparative liquid chromatography.
[0174] TLS00190 has the following chemical structure: [ka]
[0175] Example 8: LCMS purity and mass confirmation of TLS00192, TLS00178 and TLS00190. LS / MS purity confirmation of TLS00192, TLS00178 and TLS00190 was performed by LCMS. Briefly, LCMS using an Acquity H-class system (Waters, Miford, Mass.) equipped with either an Acquity BEH C18 column (50×2.1 mm, 1.7 μm) or a C18 peptide CSH column (100×2.1 mm, 1.7 μm) was maintained at 40° C. or 60° C. in a gradient of acetonitrile mobile phase containing 0.1% formic acid. Detection was performed using a QDA ESI mass spectrometer.
[0176] Results in Figures 6-8 show HPLC UV traces showing the purity and mass confirmation of TLS00192 (Figure 6), TLS00178 (Figure 7) and TLS00190 (Figure 8). All compounds were manufactured with purities meeting or exceeding 90%, and the MS ionization mode was optimized for each compound. Additionally, a summary of the purity and mass confirmation of TLS00192, TLS00178 and TLS00190 is shown in Figure 9.
[0177] Example 9: Kinetic parameters of TLS00192 and BPA-fructose. To examine the ability of TLS00192 to deliver boron to FaDu nasopharyngeal squamous cell carcinoma cells, we investigated a range of concentrations encompassing those hypothsized to be physiologically relevant for boronophenylalanine (BPA), the boron drug currently most widely studied in BNCT clinical practice.
[0178] The FaDu cell line is a human nasopharyngeal carcinoma cell line. The cell line was identified as 10801 in 2019. The cell line was obtained from the American Type Culture Collection ("ATCC") located at University Boulevard Manassas, VA 20110-2209 USA. The cell line has the ATCC designation HTB-43™ and lot number 70014320. FaDu cells are grown in DMEM culture medium supplemented with 10% fetal bovine serum with routine passage by trypsinization and reseeding. The cell line is stored frozen in liquid nitrogen.
[0179] Additionally, boron measurements were performed by ICP OES on an Agilent 5110 ICP-OES. Data were analyzed using Agilent's ICP Expert Software, version 7.4.2.10790. Boron was measured axially at a wavelength of 249.772 nm, and the internal standard beryllium was measured axially at a wavelength of 313.042 nm. Beryllium internal standard was added to the solution at a flow rate of 1:5 before being introduced into the spray chamber via a T-connector. Finally, the concentration of boron in each sample was calculated using a standard curve using 1000, 100, 10, 1 and 0 ppb of boron.
[0180] To determine the kinetic parameters of TLS00192, boron compounds were added to FaDu cells at a final concentration of 2.5 mM in HBSS and cells were incubated for 2 h at 37 °C with shaking in a humidified 5% CO2 atmosphere. After 2 h of incubation, cells were harvested, suspended in ice-cold PBS, lysed in RIPA buffer and protein content was determined by BCA assay. A portion was also subjected to boron measurement using ICP-OES. Results were expressed as ng boron / mg cell protein / min. Kinetic parameters, velocity and Km, were determined by Michaelis-Menton nonlinear regression using Prism (GraphPad) software.
[0181] The results show that uptake saturation was reached at substrate concentrations above 5 mM and plateaued at approximately 10 mM. Both TLS00192 and BPA-fructose compounds exhibited concentration-dependent cellular uptake that was efficient and saturable, following typical Michaelis-Menten kinetics. Michaelis-Menten nonlinear regression curve fitting showed that the Km of TLS00192 was approximately 50% of the Km of BPA-fructose (1.97 mM vs. 0.84 mM, respectively), suggesting that BPA may be the preferred LAT-1 substrate. (Figure 10).
[0182] It is noted that this data is consistent with that reported for non-borylated amino acids. See KANAI et al., J. Biol. Chem. 1998, 273, 23629-23632. However, the apparent Vmax for TLS00192 is higher (8.91 vs. 15.87 ng boron mg -1 min -1 The higher rate of boron accumulation in the cell lines for TLS00192 indicates either (i) a higher uptake rate or (ii) slower efflux (i.e., better retention of TLS00192 compared to BPA-fructose).
[0183] Example 10: Cellular retention of TLS00192 and BPA-fructose in FaDu cells. Subsequently, in a cell retention study in FaDu cells, it is determined whether the efflux mediated by either LAT1 or LAT2 or other transporters is equal for BPA-fructose compared to TLS00192. "Time 0" samples were collected immediately after the first 2 hours of incubation with the compounds. Cells were then harvested at the indicated times and subjected to lysis, boron measurement and protein content. Data are expressed as % of the residual boron content of the time 0 amount.
[0184] The results in Figure 11 show that boron is gradually removed from the cells at both time points. However, the removal of TLS00192 is much slower compared to BPA-fructose. It is noted that by 16 hours there is over 40% remaining TLS00192 compared to approximately 10% remaining BPA. These results demonstrate the unique feature of TLS00192 compared to BPA, which improves the amount of boron delivered to the cells.
[0185] Example 11: LAT-1 mediated competition studies with TLS00192. System L transporter (LAT-1) mediates the transport of L-amino acids into cells and has been shown to play a major role in the uptake of BPA in BPA-based BNCT (WONGTHAI et al., Cancer Sci Vol. 106, pg. 279-286, 2015). To assess whether TLS00192 is transported via an LAT-1-dependent mechanism, we examined the ability of TLS00192 to be outcompeted by L-Phe, a substrate of LAT1. FaDu cells were incubated in HBSS medium with either 0.5 mM TLS00192 or BPA-fructose for 2 hours at 37°C in the absence (subset A) or presence (subset B) of increasing concentrations of competitor Phe, in the presence of the L-system antagonist BCH (subset C) or the LAT-1 specific inhibitor JPH203 (subset D). Cells were harvested and the amount of each boronated cell-associated compound was determined by ICP OES. The IC50 of the respective inhibitor for each compound is also shown. BPA was used as a positive control for LAT-1 mediated uptake.
[0186] The results in Figure 12A show the uptake of the pure compound in the absence of competitor. For this and subsequent studies, TLS00192 was maintained at 0.5 mM. Increasing concentrations of Phe in the range of 0.01-20 mM showed decreased uptake for both BPA and TLS00192 (see Figure 12B). It is noteworthy the unexpected result that approximately 1 log higher concentrations of L-Phe competitor were required to inhibit LAT1-mediated transport of TLS00192. The IC50 was 0.04 and 0.43 mM for L-Phe in the presence of BPA-fructose and TLS00192, respectively. The results show that TLS00192 is able to better compete with endogenous amino acids and effectively utilize LAT-1 to gain cellular accumulation compared to BPA.
[0187] Next, we evaluated the pan-LAT antagonist 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid (BCH) (Figure 12C) and the specific LAT-1 inhibitor JPH203 (Figure 12D) in a competition assay. Similar to the results in Figure 12B, BCH inhibited boron uptake in a concentration-dependent manner. BPA was more readily competed by BCH compared to TLS00192 (0.14 and 0.80 mM for BPA and TLS00192, respectively). JPH203 was an even more potent inhibitor of LAT1-mediated uptake of TLS00192 and BPA than BCH, e.g., 0.19 and 0.78 μM, respectively (Figure 12D). The results indicate that (i) TLS00192 uptake is LAT-1 mediated and (ii) a higher concentration of competitor is required to displace TLS00192 from the LAT-1 binding pocket.
[0188] Example 12: Boron uptake of TLS00190 and TLS00178 in FaDu cells. The boron uptake efficiency of TLS00190 and TLS00178 was determined using FaDu cells. After 2 h of incubation, the cells were harvested and suspended in ice-cold PBS, a portion was dissolved in RIPA buffer, and the protein content was determined by BCA assay. The remaining portion was subjected to boron measurement, which was performed using ICP-OES. BPA-fructose was used as a control. After 2 h of incubation, the amount of incorporated compound was determined based on boron measurement.
[0189] The results, expressed as ng boron per mg protein, are shown in Figure 13. TLS00190 contains B linked to a phenylalanine side chain. 12 H 11 2- TLS00178 has a boron cluster linked to the C-terminus of histidine. 12 H 11 2- As shown, both of these compounds modified with 12 boron clusters on their respective side chains or on the C-terminus retain the ability to be transported into FaDu cancer cells.
[0190] Furthermore, the retention of TLS00190 and TLS00178 after the first 2 hours of uptake in FaDu cells was also studied compared to BPA-fructose. As shown in Figure 14, BPA-fructose was removed from the cells to a level of about 8% at 20 hours, similar to what was seen before, but TLS00190 and TLS00178 were retained at levels of 43% and 57%. Notably, TLS00190 cellular levels dropped to a level of 14% at 2 hours, but rose again to 43% at 20 hours, suggesting their ability to reaccumulate in cells after excretion. These characteristics of TLS00190 and TLS0078 suggest the possibility of better accumulation and retention in cancer cells of BNCT patients compared to BPA-fructose.
[0191] Example 13: Human clinical trials for the treatment of human carcinomas through the use of BAAs. BAAs are synthesized according to the present invention, which specifically accumulate in tumor cells and are used to treat certain tumors as well as other immune disorders and / or other diseases. In relation to each of these indications, two clinical approaches have been successfully pursued.
[0192] I.) Adjuvant Therapy: In adjuvant therapy, patients are treated with BAA in combination with chemotherapeutic or drug or biologic agent or combinations thereof. The primary cancer target is treated and then irradiated by the addition of BAA under standard protocols. The protocol design addresses efficacy as assessed by examples including but not limited to reduction in tumor burden of primary or metastatic lesions, extension of progression-free survival, overall survival, improvement in patient health status, disease stabilization, and the ability to reduce regular doses of standard chemotherapy and other biologic agents. These dose reductions allow additional and / or prolonged treatment by reducing dose-related toxicity of chemotherapeutic or biologic agents.
[0193] II.) Monotherapy: In relation to the use of BAA in tumor monotherapy, the BAA is administered to the patient without chemotherapy or drugs or biological agents. In one embodiment, monotherapy is clinically implemented in terminal cancer patients with widespread metastatic disease. Protocol design addresses efficacy, which is assessed by examples including, but not limited to, reduction in tumor burden in primary or metastatic lesions, extension of progression-free survival, overall survival, improvement in patient health status, disease stabilization, and the ability to reduce the usual dose of standard chemotherapy and other biological agents.
[0194] Dosage The dosage regimen may be adjusted to provide the optimum desired response. For example, a single BAA injection may be administered, several divided doses may be administered over time, or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. As used herein, "dosage unit form" refers to a physically discrete unit suitable as a unitary dosage for the mammalian subject to be treated, each unit containing a predetermined amount of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specifications of the dosage unit form of the present invention are determined by and directly depend on (a) the unique characteristics of the BAA, the individual mechanism of the irradiation mechanism (reactor) and the specific therapeutic or prophylactic effect to be achieved, and (b) the limitations inherent in the technology of compounding such compounds for the treatment of susceptibility in an individual.
[0195] Clinical Development Plan (CDP) CDP will follow and develop the treatment of cancer and / or immune disorder using the BAA of the present disclosure, which will then be irradiated using neutron capture therapy in conjunction with adjuvant or monotherapy.The study will first demonstrate safety, and then confirm efficacy in repeated administration.The study will be open-label and will compare standard treatment with BAA plus standard chemotherapy, which will then be irradiated using boron neutron capture therapy.As will be understood, one non-limiting criterion that can be utilized in conjunction with patient enrollment is the concentration of BAA in tumor, as determined by standard detection methods known in the art.
[0196] The present invention should not be limited in scope by the embodiments disclosed herein, which are intended as single illustrations of individual aspects of the invention, and any functional equivalents are within the scope of the present invention. Various modifications to the models, methods, and lifecycle methodologies of the present invention, in addition to those described herein, will be apparent to those skilled in the art from the foregoing description and teachings, and are also intended to fall within the scope of the present invention. Such modifications or other embodiments can be made without departing from the true scope and spirit of the invention. [Table 1]
Claims
1. The chemical structure: 【Chemistry 1】 A composition comprising a dosage unit form comprising a compound represented by (i) administering the composition to a patient; (ii) accumulating said dosage unit form intracellularly; and (iii) irradiating the cells with neutrons; 23. A composition comprising:
2. The composition described in claim 1, wherein the patient is a human.
3. The composition of claim 1, wherein the dosage unit form is accumulated within the cell by the LAT-1 amino acid transporter.
4. The composition of claim 1, wherein the treatment is boron neutron capture therapy (BNCT).
5. The composition of claim 1, wherein the treatment is proton boron fusion therapy (PBFT).
6. The composition described in claim 4, wherein the BNCT is used to treat cancer.
7. The composition of claim 5, wherein the PBFT is used to treat cancer.
8. A kit comprising the dosage unit form of claim 1.
9. The kit of claim 8, further comprising a label.
10. The composition described in claim 6, wherein the cancer is head and neck cancer.
11. The composition described in claim 7, wherein the cancer is head and neck cancer.
Citation Information
Patent Citations
Borylated amino acid compositions and methods for use in boron neutron capture therapy - Patents.com
JP7545987B2
Modification method to maintain uptake of synthetic amino acid in cancer cells, and neutron capture therapy to protect normal cells
WO2017175827A1
